Gilead Sciences has reported positive data from analysis of an international cohort of patients treated with remdesivir as a potential treatment for Covid-19.
The analysis reviewed 53 patients who were hospitalised with severe complications related to the novel coronavirus infection in the US, Europe, Canada and Japan.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patients received the experimental antiviral drug on an individual compassionate use basis.
